Lupin Limited
NSE: LUPIN BSE: LUPIN
NSE
1,999.60
4.40 (0.22%)
Prev Close
1995.2
Open Price
2005
Volume
1,289,535
Today Low / High
1985.8 / 2007.9
52 WK Low / High
1543 / 2402.9
Range
1,900 - 2,100
BSE
1,999.20
3.90 (0.20%)
Prev Close
1995.3
Open Price
2000.05
Volume
50,186
Today Low / High
1985.25 / 2007.55
52 WK Low / High
1531.15 / 2403.45
Range
1,899 - 2,099
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1999.6 (target range: 1,900 - 2,100), reflecting a change of 4.4 (0.22053%). On the BSE, it is listed at 1999.2 (target range: 1,899 - 2,099), showing a change of 3.9 (0.19546%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
06 Jun
2,005.00
-0.27%
05 Jun
1,954.00
2.11%
04 Jun
1,954.00
-0.51%
03 Jun
1,970.00
-0.81%
02 Jun
1,954.00
0.36%
30 May
1,970.00
-0.62%
29 May
1,960.00
0.52%
28 May
1,971.50
-1.52%
27 May
1,988.80
-0.94%
26 May
1,984.00
0.17%
23 May
1,978.00
0.05%
22 May
1,995.70
-1.35%
21 May
1,974.00
1.11%
20 May
2,037.60
-3.47%
19 May
2,072.10
-2.05%
16 May
2,084.00
-0.75%
15 May
2,100.00
-1.29%
14 May
2,066.20
0.25%
13 May
2,051.40
0.63%
12 May
1,998.00
2.09%
09 May
1,977.10
3.05%
Lupin Limited Graph
Lupin Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Lupin Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,999.60, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,999.20 | 2,019.19 | 1,817.27 - 2,221.11 |
| 2,039.18 | 1,631.35 - 2,447.02 | ||
| 2,059.18 | 1,441.42 - 2,676.93 | ||
| Bearish Scenario | 1,999.20 | 1,979.21 | 1,781.29 - 2,177.13 |
| 1,959.22 | 1,567.37 - 2,351.06 | ||
| 1,939.22 | 1,357.46 - 2,520.99 |
Overview of Lupin Limited
ISIN
INE326A01037
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,090,660
Market Cap
913,207,322,000
Last Dividend
8
Official Website
IPO Date
2001-09-10
DCF Diff
230.53
DCF
1,769
Financial Ratios Every Investor Needs
Stock Dividend of LUPIN
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-07-16 | July 16, 24 | 8 | 8 | 2024-07-16 | 2024-09-01 | |
| 2023-07-14 | July 14, 23 | 4 | 4 | 2023-07-14 | 2023-09-02 | |
| 2022-07-14 | July 14, 22 | 4 | 4 | 2022-07-15 | 2022-09-02 | |
| 2021-07-27 | July 27, 21 | 6.5 | 6.5 | 2021-07-28 | 2021-08-17 | |
| 2020-08-03 | August 03, 20 | 6 | 6 | 2020-08-04 | 2020-08-19 | 2020-05-28 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 19,656.34 Cr | 9,499.72 Cr | 10,156.62 Cr | 0.5167 | 1,526.50 Cr | 1,387.35 Cr | 2,796.64 Cr | 1,914.48 Cr | 42.05 | 3,696.94 Cr | 0.0974 |
| 2023-03-31 | 16,269.98 Cr | 9,267.53 Cr | 7,002.45 Cr | 0.4304 | 1,174.40 Cr | 1,048.78 Cr | 889.44 Cr | 430.08 Cr | 9.46 | 1,805.05 Cr | 0.0264 |
| 2022-03-31 | 16,192.79 Cr | 7,088.05 Cr | 9,104.74 Cr | 0.5623 | 1,402.36 Cr | 915.43 Cr | 1,257.99 Cr | -1,528.04 Cr | -33.65 | -438.54 Cr | -0.0944 |
| 2021-03-31 | 14,926.99 Cr | 7,693.48 Cr | 7,233.51 Cr | 0.4846 | 1,432.42 Cr | 863.40 Cr | 1,754.05 Cr | 1,216.53 Cr | 26.84 | 2,647.65 Cr | 0.0815 |
| 2020-03-31 | 15,142.80 Cr | 8,023.33 Cr | 7,119.47 Cr | 0.4702 | 1,553.79 Cr | 938.17 Cr | 1,370.54 Cr | -269.39 Cr | -5.95 | 2,031.71 Cr | -0.0178 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,187.60 Cr | 23,997.18 Cr | 9,623.73 Cr | 14,290.2900 Cr | 2,921.77 Cr | 1,734.17 Cr | 4,953.90 Cr | 5,494.22 Cr | 42.89 Cr | 189.40 Cr | -643.80 Cr | 8,501.5000 Cr |
| 2023-03-31 | 1,277.82 Cr | 22,955.93 Cr | 10,413.11 Cr | 12,464.5000 Cr | 4,541.52 Cr | 3,309.71 Cr | 4,491.76 Cr | 5,539.84 Cr | 63.16 Cr | 160.02 Cr | -498.44 Cr | 9,265.3700 Cr |
| 2022-03-31 | 1,089.92 Cr | 21,821.22 Cr | 9,599.24 Cr | 12,153.2700 Cr | 4,158.38 Cr | 3,068.46 Cr | 4,630.73 Cr | 5,397.30 Cr | 38.60 Cr | 134.24 Cr | -933.71 Cr | 8,276.4400 Cr |
| 2021-03-31 | 1,734.61 Cr | 23,610.44 Cr | 9,752.33 Cr | 13,803.1400 Cr | 5,129.08 Cr | 3,394.47 Cr | 4,092.01 Cr | 5,234.44 Cr | 0.00 Cr | 143.69 Cr | -2,378.94 Cr | 8,436.0900 Cr |
| 2020-03-31 | 2,446.33 Cr | 24,983.85 Cr | 12,402.69 Cr | 12,536.7000 Cr | 6,625.12 Cr | 4,178.79 Cr | 3,680.14 Cr | 5,123.71 Cr | 99.63 Cr | 163.65 Cr | -2,337.01 Cr | 9,225.2000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 3,648.3600 Cr | -1,712.2000 Cr | -2,184.2100 Cr | 2,719.4600 Cr | -248.0500 Cr | 983.7600 Cr | -928.9000 Cr | 2,422.2700 Cr | -1,617.1300 Cr | -182.8000 Cr | -440.1500 Cr |
| 2023-03-31 | 1,896.9800 Cr | -1,286.7700 Cr | -337.2500 Cr | 397.6200 Cr | 273.2200 Cr | 1,264.5900 Cr | -1,499.6200 Cr | 716.4900 Cr | 172.8100 Cr | -182.5000 Cr | 195.4400 Cr |
| 2022-03-31 | 367.3100 Cr | 1,292.2300 Cr | -1,572.3200 Cr | -537.7700 Cr | 87.2200 Cr | 1,013.4400 Cr | -905.0800 Cr | -1,372.2100 Cr | -1,078.7000 Cr | -295.0900 Cr | -499.3300 Cr |
| 2021-03-31 | 1,821.7600 Cr | -1,239.5800 Cr | -1,885.2700 Cr | 1,144.1400 Cr | -1,303.0900 Cr | 926.2200 Cr | -677.6200 Cr | 1,676.4500 Cr | -1,367.7100 Cr | -272.3200 Cr | -657.4200 Cr |
| 2020-03-31 | 1,468.8400 Cr | 1,106.9900 Cr | -890.5800 Cr | 795.7100 Cr | 1,685.2500 Cr | 2,229.3100 Cr | -673.1300 Cr | 876.7800 Cr | -150.4100 Cr | -226.4600 Cr | -479.5900 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 5,618.56 Cr | 1,721.55 Cr | 3,897.01 Cr | 0.6936 | 2,790.32 Cr | 855.16 Cr | 18.75 | 1,409.61 Cr | 0.1522 |
| 2024-09-30 | 5,497.01 Cr | 1,689.94 Cr | 3,807.07 Cr | 0.6926 | 1,051.36 Cr | 852.63 Cr | 18.70 | 1,382.65 Cr | 0.1551 |
| 2024-06-30 | 5,600.33 Cr | 2,963.31 Cr | 2,637.02 Cr | 0.4709 | 1,038.65 Cr | 801.31 Cr | 17.58 | 1,308.75 Cr | 0.1431 |
| 2024-03-31 | 4,895.11 Cr | 1,829.69 Cr | 3,065.42 Cr | 0.6262 | 733.10 Cr | 359.43 Cr | 7.89 | 824.85 Cr | 0.0734 |
| 2023-12-31 | 5,079.88 Cr | 1,726.08 Cr | 3,353.80 Cr | 0.6602 | 764.76 Cr | 613.12 Cr | 13.47 | 1,067.31 Cr | 0.1207 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 1,109.46 Cr | 2,431.54 Cr | 3,541.00 Cr | 5,118.98 Cr | 5,284.74 Cr | 15,020.11 Cr | 5,450.75 Cr | 25,481.96 Cr | 9,762.27 Cr |
| 2024-06-30 | -2,034.53 Cr | 4,069.06 Cr | 2,034.53 Cr | 0.00 Cr | 0.00 Cr | 2,034.53 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 1,187.60 Cr | 990.94 Cr | 2,178.54 Cr | 5,727.41 Cr | 4,953.90 Cr | 13,447.65 Cr | 5,494.22 Cr | 23,997.18 Cr | 9,623.73 Cr |
| 2023-12-31 | -1,732.89 Cr | 3,465.78 Cr | 1,732.89 Cr | 0.00 Cr | 0.00 Cr | 1,732.89 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 1,481.33 Cr | 110.04 Cr | 1,732.89 Cr | 4,464.11 Cr | 4,674.13 Cr | 12,588.47 Cr | 5,489.21 Cr | 23,443.65 Cr | 10,136.65 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 801.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 359.43 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 613.12 Cr | 514.40 Cr | 0.00 Cr | 0.00 Cr | 514.40 Cr | 2,137.25 Cr | 1,622.85 Cr | 0.00 Cr | 514.40 Cr |
| 2023-09-30 | 489.67 Cr | 495.70 Cr | 0.00 Cr | 0.00 Cr | 495.70 Cr | 1,622.85 Cr | 1,127.15 Cr | 0.00 Cr | 495.70 Cr |
| 2023-06-30 | 452.26 Cr | 469.32 Cr | 0.00 Cr | 0.00 Cr | 469.32 Cr | 1,716.44 Cr | 1,247.12 Cr | 0.00 Cr | 469.32 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2010-08-27 | August 27, 10 | 5:1 |
| 2006-08-11 | August 11, 06 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Senior Vice President of Investor Relations and M&A
Mr. Ravi Agrawal
Gender: male
Year Born:
Chief Executive Officer & Executive Director
Ms. Vinita D. Gupta
Gender: female
Year Born: 1968
MD & Executive Director
Mr. Nilesh Deshbandhu Gupta
Gender: male
Year Born: 1974
Chief Technical Operations Officer
Mr. Christoph Funke
Gender: male
Year Born:
Chief Information Officer
Mr. Sreeji Gopinathan
Gender: male
Year Born:
Company Secretary & Compliance Officer
Mr. Amit Kumar Gupta
Gender: male
Year Born:
President -Global Chief Scientific Officer
Dr. Shahin Fesharaki
Gender: Not Specified
Year Born:
Vice President & Global Head of Corporate Communications
Ms. Rajalakshmi Azariah
Gender: female
Year Born:
Executive Director, Global Chief Financial Officer, CRO & Head of API Plus SBU
Mr. Ramesh Swaminathan
Gender: male
Year Born: 1965
President of Legal and Compliance of Australia, Japan & Canada Business
Dr. Sofia Mumtaz
Gender: Not Specified
Year Born:
FAQs about Lupin Limited
Who is the CEO of the company?
The CEO is Ms. Vinita D. Gupta.
What is the current market price of the stock?
The current price is ₹1,999.60.
What is the 52-week price range?
The range is ₹1543-2402.9.
What is the market capitalization of the company?
The market capitalization is ₹91,320.73 crores.
What is the dividend yield?
The dividend yield is 0.40%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 31.79.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Lupin Limited (ISIN: INE326A01037) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹91,320.73 crores and an average daily volume of 1,090,660 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹8.